Por favor, use este identificador para citar o enlazar a este item:
http://hdl.handle.net/10261/77568
COMPARTIR / EXPORTAR:
SHARE CORE BASE | |
Visualizar otros formatos: MARC | Dublin Core | RDF | ORE | MODS | METS | DIDL | DATACITE | |
Campo DC | Valor | Lengua/Idioma |
---|---|---|
dc.contributor.author | Valbuena-Díez, Ana C. | - |
dc.contributor.author | Blanco, Francisco J. | - |
dc.contributor.author | Oujo, Barbara | - |
dc.contributor.author | Langa, Carmen | - |
dc.contributor.author | González-Nuñez, María | - |
dc.contributor.author | Llano, Elena | - |
dc.contributor.author | Pendás, Alberto M. | - |
dc.contributor.author | Díaz, Mercedes | - |
dc.contributor.author | Castrillo, Antonio | - |
dc.contributor.author | López-Novoa, José M. | - |
dc.contributor.author | Bernabéu, Carmelo | - |
dc.date.accessioned | 2013-06-05T08:54:56Z | - |
dc.date.available | 2013-06-05T08:54:56Z | - |
dc.date.issued | 2012 | - |
dc.identifier | issn: 0009-7322 | - |
dc.identifier | e-issn: 1524-4539 | - |
dc.identifier.citation | Circulation 126(22): 2612-2624 (2012) | - |
dc.identifier.uri | http://hdl.handle.net/10261/77568 | - |
dc.description.abstract | [Background]: Ischemia in the placenta is considered the base of the pathogenesis of preeclampsia, a pregnancy-specific syndrome in which soluble endoglin (sEng) is a prognostic marker and plays a pathogenic role. Here, we investigated the effects of hypoxia and the downstream pathways in the release of sEng. [Methods and Results]: Under hypoxic conditions, the trophoblast-like cell line JAR showed an increase in sEng parallel to an elevated formation of reactive oxygen species. Because reactive oxygen species are related to the formation of oxysterols, we assessed the effect of 22-(R)-hydroxycholesterol, a natural ligand of the liver X receptor (LXR), and the LXR synthetic agonist T0901317. Treatment of JAR cells or human placental explants with 22-(R)-hydroxycholesterol or T0901317 resulted in a clear increase in sEng that was dependent on LXR. These LXR agonists induced an increased matrix metalloproteinase-14 expression and activity and a significant reduction of its endogenous inhibitor, tissue inhibitor of metalloproteinase-3. In addition, mice treated with LXR agonists underwent an increase in the plasma sEng levels, concomitant with an increase in arterial pressure. Moreover, transgenic mice overexpressing sEng displayed high blood pressure. Finally, administration of an endoglin peptide containing the consensus matrix metalloproteinase-14 cleavage site G-L prevented the oxysterol-dependent increase in arterial pressure and sEng levels in mice. [Conclusions]: These studies provide a clue to the involvement of the LXR pathway in sEng release and its pathogenic role in vascular disorders such as preeclampsia. © 2012 American Heart Association, Inc. | - |
dc.description.sponsorship | This work was supported by grants from the Ministerio de Ciencia e Innovación of Spain (SAF2010-61827 to Dr Bernabeu, SAF2011-29244 to Dr Castrillo, and SAF2010-15881 to Dr Lopez-Novoa), Genoma España (MEICA; Dr Bernabeu), Instituto Reina Sofía de Investigación Nefrológica (FRIAT; Dr Lopez-Novoa), Junta de Castilla and Leon (Excellence Group Grant GR-100 to Dr Lopez-Novoa), Centro de Investigación Biomédica en Red de Enfermedades Raras (CIBERER; Dr Bernabeu), and Red de Investigación Cooperativa en Enfermedades Renales (REDINREN; Dr Lopez-Novoa). CIBERER and REDINREN are initiatives of the Instituto de Salud Carlos III of Spain supported by European Regional Development Funds (FEDER). The cardiovascular phenotyping unit, including the telemetry equipment, has been acquired with the support of FEDER. Dr Llano is recipient of a Ramón y Cajal Research contract. | - |
dc.language.iso | eng | - |
dc.publisher | American Heart Association | - |
dc.rights | closedAccess | - |
dc.title | Oxysterol-induced soluble endoglin release and its involvement in hypertension | - |
dc.type | artículo | - |
dc.identifier.doi | 10.1161/CIRCULATIONAHA.112.101261 | - |
dc.relation.publisherversion | http://dx.doi.org/10.1161/CIRCULATIONAHA.112.101261 | - |
dc.date.updated | 2013-06-05T08:54:57Z | - |
dc.description.version | Peer Reviewed | - |
dc.contributor.funder | Ministerio de Ciencia e Innovación (España) | - |
dc.contributor.funder | Fundación Genoma España | - |
dc.contributor.funder | Instituto Reina Sofía de Investigación en Nefrología (España) | - |
dc.contributor.funder | Junta de Castilla y León | - |
dc.contributor.funder | Centro de Investigación Biomédica en Red Enfermedades Raras (España) | - |
dc.contributor.funder | Red Temática de Investigación Cooperativa en Cáncer (España) | - |
dc.contributor.funder | Instituto de Salud Carlos III | - |
dc.contributor.funder | European Commission | - |
dc.identifier.funder | http://dx.doi.org/10.13039/501100004837 | es_ES |
dc.identifier.funder | http://dx.doi.org/10.13039/501100004587 | es_ES |
dc.identifier.funder | http://dx.doi.org/10.13039/501100000780 | es_ES |
dc.identifier.funder | http://dx.doi.org/10.13039/501100014180 | es_ES |
dc.type.coar | http://purl.org/coar/resource_type/c_6501 | es_ES |
item.openairetype | artículo | - |
item.grantfulltext | none | - |
item.cerifentitytype | Publications | - |
item.openairecristype | http://purl.org/coar/resource_type/c_18cf | - |
item.fulltext | No Fulltext | - |
item.languageiso639-1 | en | - |
Aparece en las colecciones: | (IIBM) Artículos (IBMCC) Artículos (CIB) Artículos |
Ficheros en este ítem:
Fichero | Descripción | Tamaño | Formato | |
---|---|---|---|---|
accesoRestringido.pdf | 15,38 kB | Adobe PDF | Visualizar/Abrir |
CORE Recommender
SCOPUSTM
Citations
82
checked on 20-abr-2024
WEB OF SCIENCETM
Citations
82
checked on 25-feb-2024
Page view(s)
477
checked on 23-abr-2024
Download(s)
110
checked on 23-abr-2024
Google ScholarTM
Check
Altmetric
Altmetric
NOTA: Los ítems de Digital.CSIC están protegidos por copyright, con todos los derechos reservados, a menos que se indique lo contrario.